Amicogen Inc
Amicogen, Inc. operates as an industrial biotechnology company in South Korea and internationally. The company develops, produces, and sells of enzymes and new materials; and produces food-related additives and health functional food. It manufactures and sells of biopharmaceutical materials and resins for purifying pharmaceutical proteins and health and beauty products. In addition, the company o… Read more
Amicogen Inc (092040) - Net Assets
Latest net assets as of September 2025: ₩101.34 Billion KRW
Based on the latest financial reports, Amicogen Inc (092040) has net assets worth ₩101.34 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩240.57 Billion) and total liabilities (₩139.22 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩101.34 Billion |
| % of Total Assets | 42.13% |
| Annual Growth Rate | 9.37% |
| 5-Year Change | -19.91% |
| 10-Year Change | 49.19% |
| Growth Volatility | 34.69 |
Amicogen Inc - Net Assets Trend (2014–2024)
This chart illustrates how Amicogen Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Amicogen Inc (2014–2024)
The table below shows the annual net assets of Amicogen Inc from 2014 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩122.50 Billion | -44.06% |
| 2023-12-31 | ₩218.97 Billion | +66.14% |
| 2022-12-31 | ₩131.80 Billion | -29.20% |
| 2021-12-31 | ₩186.16 Billion | +21.72% |
| 2020-12-31 | ₩152.94 Billion | +25.31% |
| 2019-12-31 | ₩122.05 Billion | -4.11% |
| 2018-12-31 | ₩127.28 Billion | +42.71% |
| 2017-12-31 | ₩89.19 Billion | +9.39% |
| 2016-12-31 | ₩81.54 Billion | -0.69% |
| 2015-12-31 | ₩82.10 Billion | +64.14% |
| 2014-12-31 | ₩50.02 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Amicogen Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 5623.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₩27.51 Billion | 22.46% |
| Other Components | ₩133.62 Billion | 109.09% |
| Total Equity | ₩122.50 Billion | 100.00% |
Amicogen Inc Competitors by Market Cap
The table below lists competitors of Amicogen Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
D0X
F:D0X
|
$51.79 Million |
|
Taokaenoi Food & Marketing Public Company Limited
BK:TKN
|
$51.80 Million |
|
Yangarra Resources Ltd
PINK:YGRAF
|
$51.80 Million |
|
Los Andes Copper Ltd
OTCQX:LSANF
|
$51.80 Million |
|
Birlesim Muhendislik Isitma Sogutma Havalandirma Sanayi & Ticaret Sirketi AS
IS:BRLSM
|
$51.78 Million |
|
Auburn National Bancorporation Inc
NASDAQ:AUBN
|
$51.75 Million |
|
TROPHY GAMES DEV. DK-020
F:4H7
|
$51.74 Million |
|
1S90
F:1S90
|
$51.72 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Amicogen Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 175,842,442,680 to 122,495,207,930, a change of -53,347,234,750 (-30.3%).
- Net loss of 52,791,134,750 reduced equity.
- Share repurchases of 14,800,019,040 reduced equity.
- New share issuances of 14,800,019,000 increased equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-52.79 Billion | -43.1% |
| Share Repurchases | ₩14.80 Billion | -12.08% |
| Share Issuances | ₩14.80 Billion | +12.08% |
| Other Changes | ₩-556.10 Million | -0.45% |
| Total Change | ₩- | -30.34% |
Book Value vs Market Value Analysis
This analysis compares Amicogen Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.68x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.35x to 0.68x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩4406.33 | ₩1521.00 | x |
| 2017-12-31 | ₩4647.37 | ₩1521.00 | x |
| 2018-12-31 | ₩6632.33 | ₩1521.00 | x |
| 2019-12-31 | ₩6421.93 | ₩1521.00 | x |
| 2020-12-31 | ₩8044.30 | ₩1521.00 | x |
| 2021-12-31 | ₩8796.03 | ₩1521.00 | x |
| 2022-12-31 | ₩6226.28 | ₩1521.00 | x |
| 2023-12-31 | ₩3226.16 | ₩1521.00 | x |
| 2024-12-31 | ₩2234.65 | ₩1521.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Amicogen Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -43.10%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -30.41%
- • Asset Turnover: 0.59x
- • Equity Multiplier: 2.40x
- Recent ROE (-43.10%) is below the historical average (-2.12%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 15.21% | 27.67% | 0.50x | 1.09x | ₩2.59 Billion |
| 2015 | 2.52% | 6.36% | 0.20x | 1.95x | ₩-6.14 Billion |
| 2016 | 1.95% | 2.30% | 0.47x | 1.79x | ₩-6.56 Billion |
| 2017 | -5.16% | -6.25% | 0.45x | 1.83x | ₩-13.52 Billion |
| 2018 | 31.56% | 42.50% | 0.41x | 1.82x | ₩27.44 Billion |
| 2019 | 0.07% | 0.08% | 0.48x | 1.98x | ₩-12.12 Billion |
| 2020 | 20.66% | 27.28% | 0.41x | 1.85x | ₩16.31 Billion |
| 2021 | 2.01% | 2.99% | 0.30x | 2.21x | ₩-14.88 Billion |
| 2022 | -35.83% | -32.72% | 0.34x | 3.26x | ₩-60.40 Billion |
| 2023 | -13.24% | -14.56% | 0.34x | 2.66x | ₩-40.87 Billion |
| 2024 | -43.10% | -30.41% | 0.59x | 2.40x | ₩-65.04 Billion |
Industry Comparison
This section compares Amicogen Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $185,563,423,740
- Average return on equity (ROE) among peers: 1.60%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Amicogen Inc (092040) | ₩101.34 Billion | 15.21% | 1.37x | $51.79 Million |
| Dongwha Pharm.Co.Ltd (000020) | $229.73 Billion | 2.15% | 0.36x | $75.32 Million |
| Yuhan Corp. (000100) | $323.58 Billion | 10.19% | 0.72x | $4.21 Billion |
| Yuyu Pharma Inc (000227) | $128.69 Billion | -1.72% | 0.50x | $26.44 Million |
| Ildong Holdings Co Ltd (000230) | $66.98 Billion | 10.88% | 1.80x | $49.55 Million |
| Samil Pharm (000520) | $62.87 Billion | 0.00% | 0.77x | $110.58 Million |
| Donga Socio Holdings (000640) | $328.69 Billion | 10.58% | 1.17x | $206.35 Million |
| Jw Pharmac (001060) | $223.83 Billion | 0.28% | 1.65x | $278.34 Million |
| JW Pharmaceutical Corp (001067) | $265.44 Billion | 13.94% | 1.43x | $489.75 Million |
| Samsung Pharm (001360) | $77.58 Billion | -31.98% | 0.20x | $65.82 Million |
| Ahn-Gook Pharmaceutical Co. Ltd (001540) | $148.25 Billion | 1.71% | 0.47x | $27.39 Million |